Physician profile
Sherwin B Batoon
NPI 1609947191
$11,275.11
in general payments reported to CMS, 2019-2025
41 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 94% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $1,084 · 2021: $1,167 · 2022: $1,664 · 2023: $1,725 · 2024: $2,446 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,153.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,530.02 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $1,417.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $912.60 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $897.93 | 2019-2025 | Trelegy Ellipta |
| Abbott Laboratories | $691.34 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $580.16 | 2020-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $478.39 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $451.14 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $445.40 | 2019-2024 | Livalo |
| Amgen INC. | $444.28 | 2023-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $339.71 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $311.61 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $298.09 | 2020-2025 | Verquvo, Steglatro |
| Daiichi Sankyo INC. | $269.74 | 2022-2025 | Injectafer |
| Lilly USA, LLC | $226.15 | 2019-2024 | Mounjaro |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherwin Batoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.